Lessons learned: finance and resilience in post-COVID health systems

Decoupling, deglobalisation and the price of lettuce: be careful what you wish for

Pharmaceuticals Take Centre Stage in Australian Election Campaign

Will she be right?: the ‘non-issues’ of the 2022 Australian federal election

Co-payment cut signals the end of PBS fiscal austerity?

Industry taking lead to safely manufacture antibiotics

Jane Fonda, mix tapes & Australia's 5% discount rate: when time, health economics and ethics collide

It’s the economy, stupid: the economic benefits of health spending

Is 2022 the Pharma Industry’s ‘Call of Duty’ Moment?

2022: a year in transition

The Global Pandemic Agreement: Time to Get Serious

Australians now understand there is a 'queue' for new health technologies

The rise of India's pharmaceutical sector

100 Years of Insulin: An Access to Medicines Issue Writ Large

Submission to Australia's National Medicines Policy Review

The 2021 WHO Essential Medicines List: How Pharma Can Turn Challenge into Opportunity

Medicines Australia Strategic Agreement is 'the end of the beginning'

NICE methods review, UK Life Sciences Strategy and the life sciences industry: lessons for Australia

Workers of the world resign!: What if post-pandemic staff refuse to return to the office?

Reaching the sea, the sun and the end - Day 7 C2K